Generating insulin-producing cells for diabetic therapy: Existing strategies and new development

详细信息    查看全文

• 作者：Jing Shen^a ; ^b ; ^c ; ¹ ; Yu Cheng^a ; ^b ; ¹ ; Qingwang Han^b ; Yiming Mu^a ; ^{muyiming@301hospital.com.cn} ; Weidong Han^b ; ^{hanwdrsw69@yahoo.com}
• 关键词：Diabetes therapy ; Existing strategy ; Insulin producing cell ; In situ regeneration
• 刊名：Ageing Research Reviews
• 出版年：2013
• 出版时间：March, 2013
• 年：2013
• 卷：12
• 期：2
• 页码：469-478
• 全文大小：968 K

文摘

Type 1 and 2 diabetes are characterized by a deficiency in ¦Â-cell mass, which cannot be reversed with existing therapeutic strategies. Therefore, restoration of the endogenous insulin-producing cell mass holds great promise for curing diabetes in the future. Since the initial induction of insulin-producing cells (IPCs) from embryonic stem (ES) cells in 1999, several strategies and alternative cell sources have been developed to generate ¦Â-like cells, including direct differentiation from ES cells or induced pluripotent stem (iPS) cells, proliferation of existing adult ¦Â-cells, and reprogramming of non-pancreatic adult stem/mature cells or pancreatic non-¦Â-cells to ¦Â-like-cells. However, several barriers persist in the translation of the aforementioned strategies into clinically applicable methods for IPC induction. We briefly review the most relevant studies for each strategy, and discuss the comparative merits and drawbacks. We propose that ex vivo patient-specific IPCs generated from iPS cells may be practical for cell transplantation in the near future, and in situ regeneration of IPCs from cells within the pancreas may be preferable for diabetes therapy.